Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 203

1.

The cost and incidence of prescribing errors among privately insured HIV patients.

Hellinger FJ, Encinosa WE.

Pharmacoeconomics. 2010;28(1):23-34. doi: 10.2165/11313810-000000000-00000.

PMID:
20014874
2.

Inappropriate drug combinations among privately insured patients with HIV disease.

Hellinger FJ, Encinosa WE.

Med Care. 2005 Sep;43(9 Suppl):III53-62.

PMID:
16116309
3.
4.
5.

Prevalence of possible drug-drug interactions between antiretroviral agents in different age groups in a section of the private health care sector setting in South Africa.

Katende-Kyenda NL, Lubbe MS, Serfontein JH, Truter I.

J Clin Pharm Ther. 2008 Aug;33(4):393-400. doi: 10.1111/j.1365-2710.2008.00930.x.

PMID:
18613857
6.
7.

Cost effectiveness of lopinavir/ritonavir compared with atazanavir plus ritonavir in antiretroviral-experienced patients in the US.

Simpson KN, Jones WJ, Rajagopalan R, Dietz B.

Clin Drug Investig. 2007;27(7):443-52. Erratum in: Clin Drug Investig. 2007;27(8):564.

PMID:
17563124
8.

Healthcare utilization and costs of patients with rosacea in an insured population.

Romanowicz M, Stephenson JJ, Del Rosso JQ, Lenhart G.

J Drugs Dermatol. 2008 Jan;7(1):41-9.

PMID:
18246697
9.

Efficacy and safety of atazanavir-based highly active antiretroviral therapy in patients with virologic suppression switched from a stable, boosted or unboosted protease inhibitor treatment regimen: the SWAN Study (AI424-097) 48-week results.

Gatell J, Salmon-Ceron D, Lazzarin A, Van Wijngaerden E, Antunes F, Leen C, Horban A, Wirtz V, Odeshoo L, Van den Dungen M, Gruber C, Ledesma E; SWAN Study Group.

Clin Infect Dis. 2007 Jun 1;44(11):1484-92. Epub 2007 Apr 25.

10.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for the Treatment of HIV.

MMWR Recomm Rep. 2002 May 17;51(RR-7):1-55.

11.

Guidelines for using antiretroviral agents among HIV-infected adults and adolescents.

Dybul M, Fauci AS, Bartlett JG, Kaplan JE, Pau AK; Panel on Clinical Practices for Treatment of HIV.

Ann Intern Med. 2002 Sep 3;137(5 Pt 2):381-433.

PMID:
12617573
12.

Tipranavir: PNU 140690, tipranivir.

[No authors listed]

Drugs R D. 2006;7(1):55-62. Review.

PMID:
16620137
13.

Medication error in the care of HIV/AIDS patients: electronic surveillance, confirmation, and adverse events.

DeLorenze GN, Follansbee SF, Nguyen DP, Klein DB, Horberg M, Quesenberry CP Jr, Blick NT, Tsai AL.

Med Care. 2005 Sep;43(9 Suppl):III63-8.

PMID:
16116310
14.

Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy.

Anis AH, Hogg RS, Wang XH, Yip B, Palepu A, Montaner JS, O'Shaughnessy MV, Schechter MT.

Pharmacoeconomics. 1998 Jun;13(6):697-705.

PMID:
10179705
15.

Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.

Van Vaerenbergh K.

Verh K Acad Geneeskd Belg. 2001;63(5):447-73. Review.

PMID:
11813503
16.

Costs of HIV medical care in the era of highly active antiretroviral therapy.

Gebo KA, Chaisson RE, Folkemer JG, Bartlett JG, Moore RD.

AIDS. 1999 May 28;13(8):963-9.

PMID:
10371178
17.

Atazanavir/ritonavir: a review of its use in HIV therapy.

von Hentig N.

Drugs Today (Barc). 2008 Feb;44(2):103-32. doi: 10.1358/dot.2008.44.2.1137107. Review.

PMID:
18389089
18.

Acute/subacute herpes zoster: healthcare resource utilisation and costs in a group of US health plans.

Insinga RP, Itzler RF, Pellissier JM.

Pharmacoeconomics. 2007;25(2):155-69.

PMID:
17249857
19.

Atazanavir: a review of its use in the management of HIV infection.

Swainston Harrison T, Scott LJ.

Drugs. 2005;65(16):2309-36. Review.

PMID:
16266202
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk